High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus ara-C on leukemic cells from patients with AML

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 641-646

  Löfgren, Christina ^a   Albertioni, F ^a,b   Paul, C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Cladribine; Cytarabine; Cytotoxicity; Fludarabine; In vitro chemosensitivity

Indexed keywords

CLADRIBINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BIOLUMINESCENCE; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CROSS RESISTANCE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLADRIBINE; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; VIDARABINE;

EID: 26444569474     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000175157.94192.dc     Document Type: Article

References (47)

1. Mayer RJ. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol. 1987;14:384-396.
2. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood. 1987;69:1551-1562.
3. Leith CP, Kopecky KJ, Chen I-M, et al. Frequency and clinical significance of the expression of multidrug resistance proteins as MDR 1/P-glycoprotein, MRP 1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood. 1999;94:1086-1099.
4. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507-523.
5. Boleti H, Coe IR, Baldwin SA, et al. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology. 1997;36:1167-1179.
6. Estey E, Plunkett W, Dixon D, et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia. 1987;1:580-583.
7. Kessel D, Hall TC, Wodinsky I. Transport and phosphorylation as factors in the antitumor activity of cytosine arabinoside. Science. 1967;156:1240.
8. Momparler RL, Fischer GA. Mammalian deoxynucleotide kinase I. Deoxycytidine kinase: Purification, properties and kinetic studies with cytosine arabinoside. J Biol Chem. 1968;243:4298.
9. Liliemark J, Plunkett W, Dixon D. Relationship of 1-beta-D- arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′ triphosphate levels in leukemic cells during treatment wiht high-dose 1-beta-arabinfuranosylcytosine. Cancer Res. 1985;45:5952-5957.
10. Kees UR, Ford J, Dawson VM, et al. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Res. 1989;49:3015-3019.
11. Veuger MJ, Honders MW, Landegent JE, et al. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood. 2000;96:1517-1524.
12. Owens JK, Shewach DS, Ullman B, et al. Resistance to 1-beta-D- arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 1992;52:2389-2393.
13. Nyce J, Liu L, Jones PA. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res. 1986;14:4353-4367.
14. Spasokoukotskaja T, Sasvari-Szekely M, Keszler G, et al. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur J Cancer. 1999;35:1862-1867.
15. Laliberte J, Momparler RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res. 1994;54:5401-5407.
16. m 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur J Biochem. 1999;261:689-697.
17. Chunduru SK, Appelman JR, Blakely RL. Activity of human DNA polymerase alfa and beta with 2-chloro-2′-deoxyadenosine triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys. 1993;302:19-30.
18. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737-743.
19. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993;81:143-150.
20. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA. 1998;95:9567-9571.
21. Piro LD, Ellison DJ, Saven A. The Scripps clinic experiment with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma. 1994;14:121-125.
22. Juliusson G, Hoglund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol. 2003;123:810-818.
23. Santana VM, Hurwitz CA, Blakely R, et al. Complete hematological remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute leukemia. Blood. 1994;84:1237.
24. Santana V, Mirro J, Kearns C, et al. 2-Chlorodeoxyadenosine produces a high rate of complete remissions in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364-370.
25. Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute leukemia in adults. Leukemia. 1996;10:1563-1569.
26. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetics, pharmacodynamic and molecular interactions. Blood. 1996;87:256-264.
27. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma. 2003;44:1705-1712.
28. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93-103.
29. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875-890.
30. Spriggs DR, Stopa E, Mayer RJ, et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46:5953-5958.
31. Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74-79.
32. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124.
33. Gandhi V, Estey E, Keating MJ, et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993;10 (Suppl):109-114.
34. Carella AM, Cascavilla N, Greco MM, et al. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma. 2001;40:295-303.
35. Tosi P, Visani G, Ottaviani E, et al. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia. 1994;8:2076-2082.
36. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265-271.
37. Paul C, Peterson C, Gahrton G, et al. Uptake of free and DNA-bound daunorubicin and doxorubicin in human leukemic cells. Cancer Chemother Pharmacol. 1979;2:49-52.
38. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′ deoxyadenosine in humans. Cancer Res. 1991;51:5570-5572.
39. Liliemark J, Albertioni F, Hassan M, et al. On the bioavailablility of oral and subcutaneous 2-chlorodeoxyadenosine in humans: alternative routes of administrations. J Clin Oncol. 1992;10:1514-1518.
40. Sundman-Engberg B, Tidefelt U, Liliemark J, et al. Intracellular concentrations of anticancer drugs in leukemic cells in vitro vs. in vivo. Cancer Chemother Pharmacol. 1990;25:252-256.
41. Rhedin A-S, Tidefelt U, Jönsson K, et al. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res. 1993;3:271-276.
42. Lundin A, Hasenson M, Persson J, et al. Estimation of biomass in growing cell lines by adenosine triphosphate assay. Methods Enzymol. 1986;133:23.
43. Tidefelt U, Sundman-Engberg B, Rhedin A-S, et al. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Hematol. 1989;43:374-384.
44. Mollgard L, Tidefelt U, Sundman-Engberg B, et al. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res. 2000;24:445-452.
45. Kristensen J, Nygren P, Liliemark J, et al. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia. 1994;8:1712-1717.
46. Mansson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003;65:237-247.
47. Mollgard L, Prenkert M, Smolowicz A, et al. In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia. Leuk Lymphoma. 2003;44:783-789.